PharmaFocus Today – Page 41 – media

Kangtai Biological’s revenue in the first quarter of 2025 increased by more than 40% year-on-year, and multiple projects such as the pentavalent vaccine made significant progress

The evening of April 20, Kangtai Biological (300601) released its 2024 annual report and 2025 first quarter report. The company achieved operating income of 2.652 billion yuan in 2024 and a net profit of 246 million yuan attributable to the parent company after deducting non-recurring items; operating income in the first quarter of 2025 was 645 million yuan, a year-on-year increase of 42.85%; net profit attributable to the parent company after deducting non-recurring items was 17 million yuan, a year-on-year increase of 17.56%. The annual report shows that Kangtai Biological’s R&D investment in 2024 was 569 million yuan, accounting for 21.47% of the operating income of the year, and the cumulative R&D investment in the past three years was 2.105 billion yuan, accounting for 22.67% of the cumulative operating income in the past three years. During the reporting period, Kangtai Biological’s new vaccine R&D pipeline has made a number of ...
- Source: drugdu
- 185
- April 21, 2025
The national immunization program will enter a period of dynamic adjustment, and many new vaccines are expected to be included

On the morning of April 19, the 2025 Vaccine and Health Conference was held. Shen Hongbing, deputy director of the National Health Commission and director of the National Disease Control Bureau, shared his outlook and ideas on the future adjustment model of the national immunization program in his speech. Shen Hongbing said that one direction in the future is to dynamically adjust and optimize the national immunization program strategy, and optimize it according to the principles of overall planning, dynamic adjustment, and step-by-step implementation. “We are preparing to make a five-year plan,” he said. The future goal is to gradually narrow the gap between the domestic immunization program and the international level, and gradually include vaccines that need to be included. The last time China substantially included a new vaccine was in 2007. The adjustments in recent years mainly involve vaccination procedures and strategies. Therefore, there is a gap between ...
- Source: drugdu
- 195
- April 21, 2025
Beike Biotech’s revenue and net profit both fell, sales of herpes zoster vaccines decreased, and the core of marketing left

On the evening of April 20, Beike Biotech (688276) released its 2024 annual report showing that during the reporting period, the company’s operating income was approximately 1.229 billion yuan, a year-on-year decrease of 32.64%; the corresponding attributable net profit was approximately 232 million yuan, a year-on-year decrease of 53.67%. It is planned to pay a cash dividend of 1.69 yuan (including tax) per 10 shares to all shareholders. In this regard, the annual report pointed out that the main reason was the decrease in revenue and net profit due to the decrease in sales of herpes zoster vaccines during the reporting period; the net cash flow generated by operating activities was 406.5022 million yuan, 255.2070 million yuan in the same period last year, an increase of 59.28%, mainly due to the increase in sales proceeds; basic earnings per share, diluted earnings per share, basic earnings per share after deducting non-recurring ...
- Source: drugdu
- 194
- April 21, 2025
High incidence recently, no vaccine to prevent! Guangdong reports 1542 cases of scarlet fever

Recently, the number of cases of scarlet fever in Guangdong, Hunan and other places has increased. In the absence of an effective vaccine, how to correctly understand scarlet fever and scientifically prevent it has received high attention. On April 14, the Guangdong Provincial Disease Control and Prevention Bureau announced the provincial statutory infectious disease epidemic situation in March 2025. Among them, the number of scarlet fever cases reported in Guangdong Province in March was 1542, an increase of 641 cases from February. On April 17, Hu Yan, deputy director of the Children’s Medical Center of the First Affiliated Hospital of Hunan University of Chinese Medicine, said that the number of children with scarlet fever seen in the hospital’s pediatric outpatient and emergency departments has increased recently. “This year’s spring in the south is relatively dry, which is conducive to the survival and spread of group A hemolytic streptococci.” On April ...
- Source: drugdu
- 158
- April 21, 2025
Weixinkang’s wholly-owned subsidiary obtains approval for clinical trial of succinylated gelatin injection

April 16, Weixinkang(603676) issued an announcement that its wholly-owned subsidiary Baiyi Pharmaceutical recently received the “Drug Clinical Trial Approval Notice” for Succinylated Gelatin Electrolyte Sodium Acetate Injection approved and issued by the National Medical Products Administration. The drug is an injection with a specification of 500 mg, and the application is for clinical trials. The approval conclusion shows that the clinical trial application for succinylated gelatin electrolyte sodium acetate injection meets the relevant requirements for drug registration and is approved for clinical trials. As of March 2025, the company’s cumulative R&D investment in this drug is approximately RMB 3.15 million. As a colloidal plasma volume substitute, succinylated gelatin electrolyte sodium acetate injection is mainly used for the treatment of hypovolemia and shock, and can be used in combination with crystalloid solutions. The announcement also mentioned that B. Braun Medical’s similar drug has been approved for marketing, and five other companies ...
- Source: drugdu
- 109
- April 18, 2025
The first treatment guideline for Asian pancreatic cancer patients was released, and therapeutic vaccines also officially entered the clinic

On April 15, 2025, during the National Cancer Prevention and Treatment Publicity Week, the international authoritative journal “European Society for Medical Oncology Gastrointestinal Oncology” officially released the “Asian Expert Consensus on Systemic Treatment of Pancreatic Cancer” (hereinafter referred to as “Asian Consensus”), filling the gap in the previous Asian pancreatic cancer diagnosis and treatment standards. As the core developer of the Asian consensus, Professor Shen Baiyong, Vice President of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Director of the Pancreatic Disease Center, told the reporter of China Business News: “This important achievement demonstrates China’s global influence in the field of pancreatic cancer diagnosis and treatment, and marks that Asian pancreatic cancer diagnosis and treatment has entered a new stage. We have not only solved key problems in clinical practice, but also let the international academic community hear the strong voice from Asia.” Although there have been ...
- Source: drugdu
- 209
- April 17, 2025
The first influenza vaccine bidding this year was announced, and each shot costs only 10 yuan

On April 14, according to the Shenzhen Government Procurement Network, the Shenzhen Center for Disease Control and Prevention announced the results of the city’s influenza vaccination project for people aged 60 and above. Hualan Vaccine (full name “Hualan Biological Vaccine Co., Ltd.”) won the bid for the trivalent influenza vaccine at 10 yuan per shot. It is understood that this is also the first influenza vaccine bidding project in the country this year. In recent years, the winning bid price of public influenza vaccines has declined significantly, and the winning bid price of products has occurred several times at about 10 yuan per shot. Interface News previously reported that in October last year, Beijing Kexing’s trivalent influenza vaccine won the bid at a price of 10.5 yuan per shot. At that time, Fosun Yalifeng, which participated in the same bidding, quoted as low as 6.5 yuan per shot. In September ...
- Source: drugdu
- 158
- April 17, 2025
Obtained Korean Drug Registration Certificate

On April 15, Tonghe Pharmaceutical announced that the company recently received the drug registration certificate for Asartan Potassium issued by the Korean Ministry of Food and Drug Safety. The manufacturer’s name is Jiangxi Tonghe Pharmaceutical Co., Ltd., the manufacturer’s address is Fengxin High-tech Industrial Park, Jiangxi Province, the certification scope is Asartan Potassium API, the certificate number is 2025-A1-0844, and the issuance date is 2025.04.14. Asartan Potassium is suitable for the treatment of primary hypertension in adults. The company’s Asartan Potassium product has obtained the Korean Drug Registration Certificate, which means that the company’s Asartan Potassium API has obtained access to the Korean market, which will play a positive role in the company’s further expansion of international market business. https://finance.eastmoney.com/a/202504153377409386.html
- Source: drugdu
- 142
- April 17, 2025
China’s first AAV gene therapy breaks through

Recently, China’s gene therapy field has ushered in a historic breakthrough – Xinxin Pharmaceutical’s AAV gene therapy Xinjiuning® (BBM-H901 injection, generic name: Bopidarcoside injection) was approved for marketing, becoming the first approved gene therapy drug for hemophilia B in China. The code to break the game The breakthrough of BBM-H901 is not only reflected in the innovation of the technical path, but also in the overall leap in its clinical value. Through precise gene delivery and long-term expression mechanism, the drug breaks the limitations of traditional therapies and opens a new era in the treatment of hemophilia. From the perspective of annualized bleeding rate, the annualized bleeding rate of patients under traditional treatment is usually high. The ABR determined for the domestic preventive treatment population is about 5.0, while the average ABR of subjects after treatment with BBM-H901 injection is only 0.6 (95% Cl: 0.18-1.99). This means that the bleeding ...
- Source: drugdu
- 260
- April 17, 2025
Merck’s 9-valent HPV vaccine has been approved for marketing in men; New Hecheng’s net profit increased by 117.01% year-on-year |

NO.1 New Novartis ADC drugs approved for clinical trials in the United States On April 14th, Novo Nordisk announced that its controlling subsidiary, Jushi Bio, has recently received a notification from the US Food and Drug Administration (FDA) that its clinical trial application for injectable SYS6041 drug, filed by Jushi Bio, has been approved by the FDA and can be conducted in the United States. SYS6041 is a monoclonal antibody conjugated drug (ADC) that can bind to specific receptors on the surface of tumors, enter cells through endocytosis, and release toxins, achieving the effect of killing tumor cells. The clinical indication approved this time is advanced solid tumor. Comment: This event is an important breakthrough in the company’s internationalization research and development process, which not only enhances the company’s market attention in the field of innovative drugs, but also brings potential opportunities for future performance growth. However, given the ...
- Source: drugdu
- 164
- April 16, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.